Exelixis teams up with Roche in cancer; shares up 3% premarket

Dec. 19, 2019 7:27 AM ETExelixis, Inc. (EXEL), RHHBYBy: Douglas W. House, SA News Editor4 Comments
  • Exelixis (NASDAQ:EXEL) inks an agreement with Roche (OTCQX:RHHBY) aimed at evaluating the combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic solid tumors.
  • The companies will co-fund three late-stage studies in advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma.
  • EXEL is up 3% premarket on light volume.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.